Zhejiang East Asia Pharmaceutical Co., Ltd. (605177.SS)
CNY 16.71
(-0.83%)
CNY 16.71
(-0.83%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 211.78 Million CNY | 33.64% |
| 2022 | 168.8 Million CNY | 17.76% |
| 2021 | 143.34 Million CNY | -12.94% |
| 2020 | 164.66 Million CNY | 14.59% |
| 2019 | 143.69 Million CNY | 5.63% |
| 2018 | 136.04 Million CNY | 5.62% |
| 2017 | 128.8 Million CNY | 5.67% |
| 2016 | 121.89 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 61.53 Million CNY | 4.8% |
| 2024 Q1 | 58.71 Million CNY | -9.64% |
| 2024 Q3 | 76.41 Million CNY | 21.73% |
| 2023 Q4 | 64.98 Million CNY | 4.56% |
| 2023 FY | 225.58 Million CNY | 33.64% |
| 2023 Q3 | 62.14 Million CNY | 27.57% |
| 2023 Q2 | 48.71 Million CNY | -2.04% |
| 2023 Q1 | 49.73 Million CNY | 12.18% |
| 2022 FY | 168.8 Million CNY | 17.76% |
| 2022 Q3 | 48.38 Million CNY | 26.41% |
| 2022 Q2 | 38.27 Million CNY | 1.22% |
| 2022 Q1 | 37.81 Million CNY | -2.3% |
| 2022 Q4 | 44.33 Million CNY | -8.37% |
| 2021 Q2 | 21.8 Million CNY | -45.61% |
| 2021 Q1 | 40.08 Million CNY | -3.66% |
| 2021 FY | 143.34 Million CNY | -12.94% |
| 2021 Q4 | 38.7 Million CNY | -9.47% |
| 2021 Q3 | 42.75 Million CNY | 96.1% |
| 2020 FY | 164.66 Million CNY | 14.59% |
| 2020 Q4 | 41.6 Million CNY | 13.03% |
| 2020 Q3 | 36.81 Million CNY | -18.11% |
| 2020 Q2 | 44.94 Million CNY | 8.86% |
| 2020 Q1 | 41.29 Million CNY | -1.15% |
| 2019 Q4 | 41.77 Million CNY | 17.2% |
| 2019 Q3 | 35.64 Million CNY | 0.0% |
| 2019 FY | 143.69 Million CNY | 5.63% |
| 2018 FY | 136.04 Million CNY | 5.62% |
| 2017 FY | 128.8 Million CNY | 5.67% |
| 2016 FY | 121.89 Million CNY | 0.0% |